Avery Dennison Corp
Packaging
Avery Dennison Corp (AVY) Stock News
The latest AVY headlines and market coverage — 2 recent stories, updated throughout the day.
- Benzinga·
Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder
Johnson & Johnson announced that IMAAVY (nipocalimab-aahu) achieved its primary endpoint in the Phase 2/3 ENERGY study for warm autoimmune hemolytic anemia (wAIHA). Patients receiving the 30 mg/kg dose were three times more likely to achieve durable hemoglobin improvements compared to placebo over 24 weeks. The drug demonstrated rapid onset of effect, early improvements in fatigue, and reduced steroid use, with a safety profile consistent with its approved indication in myasthenia gravis. The supplemental Biologics License Application has been granted FDA Priority Review.
- Benzinga·
Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder
Johnson & Johnson (NYSE: JNJ ) on Thursday presented detailed results from its Phase 2/3 ENERGY study showing that IMAAVY (nipocalimab-aahu) achieved a statistically significant, durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA). The rare blood disorder occurs when the immune system mistakenly produces IgG antibodies that attack and destroy healthy red blood cells at normal body temperatures . data-variant="card" data-news-mode="manual" > Read Also: Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 JNJ Drug Demonstrates Durable Hemoglobin Response The company said patients receiving the 30 mg/kg dose experienced a rapid onset of effect and were about three times more likely to achieve durable hemoglobin improvements than those receiving a placebo over 24 weeks . The randomized, placebo-controlled trial ... Full story available on Benzinga.com